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CGRP = calcitonin gene-related peptide; DC = dendritic cell; IFN-γ = interferon-γ; IL = interleukin; NANC = nonadrenergic and noncholinergic; 
R = receptor; SP = substance P; TCR = T cell receptor; VIP = vasoactive intestinal peptide.
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Introduction
Homeostasis within the body is regulated by three inter-
woven systems: the endocrine, nervous and immune
systems [1]. It is increasingly clear that exchange of infor-
mation between these systems is facilitated by the
endocrine and/or paracrine release of hormones, neuro-
mediators and cytokines by either of these systems and by
the shared expression of reciprocal receptors for these
mediators. As an example, T lymphocytes express neu-
ropeptide receptors for substance P (SP), calcitonin gene-
related peptide (CGRP), somatostatin and vasoactive
intestinal peptide (VIP). These neuropeptides are released
from the unmyelinated nerve endings within the central
lymphoid organs and peripheral tissues. At the same time,
neural cells express receptors for cytokines, which are
released from the immune system in a paracrine fashion
and affect neural growth and differentiation. To complicate
things further, immune cells themselves can produce
neuropeptides, which influence nervous or immune cells in
a paracrine or autocrine fashion.
In this commentary the pivotal role of neuropeptides in the
process of T cell activation is discussed against the cur-
rently prevailing paradigm of T cell activation by profes-
sional antigen-presenting dendritic cells (DCs) [2]. In this
paradigm, the first step in the adaptive immune response
of the T cell is the recognition and uptake of antigen by
immature DCs derived from bone marrow that reside in
the periphery of the body and the marginal zone of the
spleen, followed by processing of the antigen into an
MHC-associated peptide that can be recognised by the
T cell receptor (TCR).
DCs are professional antigen-presenting cells for three
reasons. First, they express many pattern-recognition
receptors for foreign antigen and have the necessary intra-
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cellular enzymes to degrade the antigen into immunogenic
peptides. Second, an encounter with ‘dangerous’ antigens
induces the functional maturation of DCs and their migra-
tion into the T cell area of draining lymph nodes and
spleen, carrying the antigenic cargo into the sites of T cell
recirculation. Third, when mature DCs have reached the
draining lymph node and spleen, they express co-stimula-
tory molecules such as CD80, CD86 and intercellular cell-
adhesion molecule-1 (ICAM-1) (which are necessary for
optimal T cell activation and the avoidance of T cell
anergy), and produce cytokines such as interleukin (IL)-12
and IL-10 that critically determine the type of T helper
response that is induced [3]. By performing these three
essential functions, DCs are the only antigen-presenting
cells that can induce a primary immune response after
transfer into unimmunized mice, whereas B cells and
macrophages fail to do so. Any discussion on the role of
neuropeptides on T cell activation should therefore take
into account not only the direct effects of these mediators
on T cells but also their indirect effects through the modu-
lation of DC function.
Anatomy of interaction of neuropeptides with
the immune system
Direct interactions between neuropeptides and immune
cells are facilitated by the well-known innervation of both
primary (thymus and bone marrow) and secondary (spleen,
lymph nodes, Peyer’s patches, tonsils) lymphoid organs by
capsaicin-sensitive nonadrenergic and noncholinergic
(NANC) primary afferent nerve endings and by autonomic
nerves containing VIP, somatostatin and neuropeptide Y
[4–6]. Within these secondary immune organs, SP and
CGRP containing afferent nerve endings of the NANC
system terminate around high endothelial venules, the sites
of specialised extravasation of recirculating T cells, and in
the T cell area and lymphoid follicles, interacting with T
cells, macrophages, mast cells and possibly DCs [6,7].
Outside the immune system, the direct interaction of nerve
endings containing SP and CGRP with DCs has been
described in the skin and in the airway epithelium [8,9].
Within these tissues, the long surface extensions of DCs
run parallel to the extensive network of unmyelinated nerve
endings, making interaction very likely [10].
Although immunohistochemical staining of thymus, spleen
and lymph nodes has demonstrated that neuropeptides
such as SP are confined mainly to unmyelinated nerve
endings [11], non-neuronal cells of the immune system
can be a source of tachykinins [5]. Human T lymphocytes
contain preprotachykinin-A mRNA, encoding SP, and
produce endogenous SP [12]. Human and rodent mono-
cytes and macrophages produce SP under baseline con-
ditions [13–15]. More importantly, murine DCs derived
from bone marrow were shown to contain mRNA for the
preprotachykinin A gene, and transcription was confirmed
by the demonstration of SP by ELISA and immunohisto-
chemistry [16]. On activation with lipopolysaccharide in
vitro there was a marked increase in SP expression by
mononuclear phagocytes and DCs [13,14,16]. The
expression of neuropeptides by these various immune
cells could be an explanation of why not all immunoreactiv-
ity for neuropeptides is confined to nerve endings within
secondary immune organs.
During the effector immune response, the process of lym-
phocyte migration also allows T cells to migrate into inflam-
matory lesions within non-lymphoid organs such as the
skin, gut, joint and lung. In these sites, lymphocyte extrava-
sation is facilitated by neurogenic inflammation and plasma
extravasation that is dependent on the release of SP from
capsaicin-sensitive primary afferent nerve endings via an
axon reflex. In a mouse model of delayed-type hypersensi-
tivity inflammation of the lung parenchyma, it was shown
that SP and VIP were released extensively (nanomolar con-
centration range) into the lung parenchyma after challenge
with sheep erythrocytes in sensitised mice, and closely fol-
lowed the kinetics of increase in lymphocytes, granulocytes
and macrophages in bronchoalveolar lavage fluid as well as
the production of cytokines. During the induction of inflam-
mation there was an increase in SP immunoreactive nerve
endings within the peribronchial and perivascular leuko-
cytic infiltrates [17]. Not only are inflammatory areas richly
supplied by NANC neurons, they also contain many inflam-
matory immune cells, known to produce neuropeptides
(namely macrophages, DCs and lymphocytes).
Eosinophils, extracted from Schistosoma mansoni-induced
liver granulomas, have been shown to produce SP that can
influence interferon-γ (IFN-γ) production by intralesional T
lymphocytes [18,19]. The same granulomatous lesions
also contain immunoreactive somatostatin and VIP [20].
Sites of inflammation within the lung are therefore poten-
tially important areas of interaction between effector
immune cells and locally released neuropeptides.
SP as an immunostimulatory neuropeptide
The NANC nervous system acts through neuropeptide
mediators such as the tachykinins SP, neurokinin A and
neurokinin B. There are at least three distinct tachykinin
receptors: neurokinin-1 receptor (NK-1R), NK-2R and NK-
3R, which bind preferentially to SP, neurokinin A and neu-
rokinin B, respectively [5]. SP is the most widely studied
member of the tachykinin family and modulates a number
of important immunological functions, among which are
direct effects on T cell activation. Physiological concentra-
tions of exogenously added SP (10–11 to 10–13 M)
augment antigen- and mitogen-induced production of IL-2
[21,22] and proliferation in T lymphocytes in vitro and in
vivo [23–25]. After administration of SP to normal and
neonatal capsaicin-treated rats, there was an increase in
concanavalin A-induced proliferation of spleen and periph-
eral blood lymphocytes, which correlated with an
enhanced production of IL-2 and expression of the IL-2R,
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CD25, on CD4+ T cells. Moreover, SP markedly enhanced
the percentage of circulating CD25+ CD4+ T cells in the
peripheral blood [26].
Another well-known effect of SP is the stimulation of IFN-γ
production by T cells, an effect that could be due to
enhanced IL-12 production by antigen-presenting cell
types [19,27,28]. With few exceptions, the immunomodu-
latory effects of SP on lymphocytes can be inhibited by
pharmacological antagonists of NK-1R such as the non-
peptide antagonist SR140333 [22,26]. Moreover, bio-
chemical and molecular evidence has been obtained that
human [12,29,30] and murine lymphocytes [18,31]
express NK-1R but not NK-2R or NK-3R. Human mono-
cytes were also shown to contain NK-1R, particularly
when obtained from lamina propria of mucosal tissues
[32]. Lung and skin DCs also contain binding sites for SP,
most probably NK-1R [9].
The demonstration that most immunocytes (monocytes,
DCs and lymphocytes) producing SP also express its
receptor led to the hypothesis that SP not only acts as a
mediator of the crosstalk between the nervous and immune
systems but is also biologically involved in the direct interac-
tion between immune cells in a paracrine and/or autocrine
fashion, independently of sensory nerves or neurogenic
inflammation [12,14,16]. Because DCs are highly involved
in the induction and regulation of many immune responses,
we have examined the endogenous expression of SP by
DCs and studied its role in the activation of T lymphocytes.
On co-culture of DCs and allogeneic or syngeneic ovalbu-
min-specific T cells the addition of a specific NK-1R antago-
nist, SR140333, led to a decrease in T lymphocyte
proliferation induced by DCs, an effect that was enhanced
when blocking the co-stimulatory CD80/86–CD28
pathway. These findings were confirmed by the use of
responder T cells derived from NK-1R knockout animals,
ruling out any toxic effects of SR140333 on the observed
effects. Moreover, when purified naive NK-1R–/– T cells
were stimulated with stimulatory anti-TCR and anti-CD28
antibodies in the absence of DCs, there was a decrease in
T cell proliferation, revealing the autocrine release of stimu-
latory SP by T cells themselves [16]. Indeed, T cells have
been shown to transcribe the mRNA for preprotachykinin A
and release SP on activation with capsaicin [12].
From a number of experiments, direct autocrine and/or
paracrine effects of endogenously released SP on the
immunostimulatory capacity of DCs seem less likely,
although it has been shown that SP induces activation of
the transcription factor nuclear factor-κB in murine DCs
[9,16,33]. This transcription factor was previously shown
to be pivotal in the upregulation of stimulatory activity in
DCs by upregulating the expression of MHC class II, the
co-stimulatory molecules CD86 and CD80, and levels of
IL-12 production [34]. One way in which SP might
enhance T cell responses is by recruiting DCs into sites of
damage, when it is released very rapidly from nerve
endings. SP is a chemoattractant for lung-derived DCs in
vitro and in vivo, and in this way it might stimulate the
primary immune response by enhancing immune recogni-
tion of dangerous antigens. Moreover, SP is implied in the
recruitment of DCs into sites of inflammation during sec-
ondary T cell responses in the lung and skin, and its deple-
tion leads to severely reduced delayed hypersensitivity
reactions [9]. It is currently unclear how DCs regulate the
release and activity of SP during interaction with T cells,
but one interesting study demonstrated the presence of
aminopeptidase N on the surface of bronchial mucosal
L25+ DCs in patients with asthma. This enzyme has the
potential to break down SP [35].
CGRP, somatostatin and VIP as generally
suppressive neuropeptides
CGRP is released simultaneously with SP from capsaicin-
sensitive nerve endings. In contrast with SP, CGRP
directly suppresses IL-2 production and proliferation in
murine T cells [36]. In addition, CGRP-containing nerve
endings are found in close proximity to skin Langerhans
cells, and CGRP has several suppressive effects on DC
activation [8,37]. Pretreatment of murine skin DCs with
CGRP led to a decrease in alloresponses in the mixed
lymphocyte reaction, as well as a decrease in ovalbumin-
specific T cell responses of syngeneic T cells [8]. The
mechanism by which CGRP mediates its effects on DCs
is slowly being discovered. Signalling via the type I CGRP
receptor expressed on human monocyte-derived DCs and
long-lived murine DC cell lines leads to an increase in
intracellular free Ca2+ and to a decreased expression of
MHC class II, the co-stimulatory molecule CD86, and to a
decreased production of IL-12, an effect that could be due
to an enhanced production of IL-10 by these DCs [37,38].
Somatostatin is a widespread neuropeptide with generally
inhibitory function on hormone release in the anterior pitu-
itary and the gastrointestinal system (for extensive review
and references see [39]). In the peripheral nervous system
it is found in sympathetic and sensory neurons innervating
the lymphoid organs, and receptors for somatostatin are
located predominantly in lymphoid follicle germinal centres
[6]. Additional non-neuronal sources of somatostatin
(such as granuloma cells within Schistosoma-induced liver
granulomata, lymphocytes, macrophages and thymic DCs)
have been described. The presence of binding sites for
somatostatin and the expression of mRNA for somato-
statin receptors (sstr1–5) on lymphocytes and monocytes
is established, although the expression of a particular
somatostatin receptor subtype on T lymphocytes seems to
vary with species and with the origins of the T cells.
Somatostatin is generally inhibitory for T cell prolifera-
tion, especially in the presence of suboptimal stimulatory
Available online http://respiratory-research.com/content/2/3/133
conditions. Indeed, the administration of antisense
oligodeoxynucleotides designed to block the translation of
somatostatin leads to an enhanced spontaneous prolifera-
tion of rat splenocytes in vitro [40]. In addition, somato-
statin suppresses the production of IFN-γ from murine and
human T lymphocytes, a finding that has deserved the
most attention within the granulomatous inflammation
induced by Schistosoma, where it generally antagonises
the stimulatory effects of SP and vice versa [20,27]. Simi-
larly, granulomata of sarcoidosis patients have been
known to bind the somatostatin receptor ligand octreotide
in vivo [39]. The precise contribution of somatostatin to
the immunostimulatory function of DCs remains to be
determined, although certain DC subsets contain
immunoreactive somatostatin.
VIP and the structurally related pituitary adenylate
cyclase-activating polypeptide (PACAP) are present
within immune microenvironments and inflammatory pul-
monary lesions and modulate a number of T lymphocyte
functions ([17]; for review and references see [41]).
Macrophages and lymphocytes themselves produce VIP.
Receptors for VIP are located predominantly at the CD3+
T cell area in lymph nodes and spleen, and include the
VPAC1 receptor (also known as PACAP type II/VIP1) and
VPAC2 receptor (PACAP type III/VIP2) [6]. Although VIP
has been known to be a suppressive neuropeptide for T
cell proliferation and production of IL-2, IL-4 and IL-10, as
well as an anti-inflammatory mediator, there are a number
of recent studies suggesting that VIP might have a dual
role, also enhancing certain lymphocyte functions by
interacting with different VIP receptors [42,43]. VIP and
PACAP inhibit the activation-induced cell death of acti-
vated T cells by inhibiting the expression of Fas ligand,
possibly leading to a prolongation of immune responses
[44]. The stimulatory effects of VIP on T cell proliferation
occurred specifically when stimulated by antigen-pulsed
antigen-presenting cells, suggesting an indirect effect of
VIP. By signalling through the VPAC1 receptor, VIP was
shown to induce the maturation of immature DCs leading
to an enhanced production of IL-12 and an enhanced
expression of the DC-maturation marker CD83, especially
in the presence of suboptimal amounts of tumour necro-
sis factor-α [45].
Conclusion and suggestions for the future
Many recent studies have illustrated the importance of
immune regulation by neuropeptides through direct
effects on T cells and indirect effects on antigen-present-
ing DCs (see Fig. 1). The accumulated data also suggest
that neuropeptides are biologically involved in the direct
interaction between immune cells in a paracrine and/or
autocrine fashion, independently of sensory nerves. These
studies have largely used in vitro systems in which con-
centrations of neuropeptides could be outside the physio-
logical range and in which no account was taken of the
normal anatomical distribution of lymphocytes and neural
innervation of lymphoid organs and peripheral tissues.
Most models that have emerged from these studies have
not integrated the effects of neuropeptides with those of
cytokines or mediators released from inflammatory cells.
For example, it is at present unclear whether and how neu-
ropeptides can modulate such important functions as T
helper cell differentiation, tolerance induction and lympho-
cyte migration. Clearly, studies in vivo on the role of neu-
ropeptides will be facilitated by the use of
pharmacological antagonists of neuropeptide receptors
and of knockout mouse strains lacking particular neu-
ropeptides or their receptors [16,17]. Ultimate proof of the
contribution of neuropeptides to human T cell-mediated
diseases awaits the results of clinical interventions with
the newer and highly selective antagonists of the various
neuropeptide receptors.
Note added in proof
Using nested PCR and monoclonal antibodies, it was very
recently shown that human and murine DCs express
NK-1R (Marriott I, Bost KL: J Neuroimmunol 2001, 114:
131–141).
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Figure 1
Summary of known effects of neuropeptides on the interaction between
dendritic cells and T cells. Neuropeptides can be released from nerve
endings innervating the primary or secondary lymphoid structures or from
nerve endings within inflammatory lesions. Alternatively, dendritic cells
and T cells can produce neuropeptides that influence immune activation
and/or suppression in an autocrine and paracrine fashion. Solid arrows
indicate stimulatory effects; broken arrows indicate inhibitory effects.
CGRP, calcitonin gene-related peptide; IFN-γ, interferon-γ; IL, interleukin;
NF-κB, nuclear factor-κB; SOM, somatostatin; SP, substance P; VIP,
vasoactive intestinal peptide.
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